What Labs Do You Need for Sermorelin? IGF-1 & Monitoring

Whether a sermorelin program orders bloodwork is one of the clearest signals of whether you're dealing with a legitimate medical provider or a vial-shipping storefront. Sermorelin works on your growth-hormone axis, and that axis touches glucose, thyroid, and IGF-1 — markers a responsible clinician checks before you start and tracks while you're on it. This guide explains exactly which labs a proper sermorelin program runs, why each one matters, and what it means when a provider skips them entirely.

Why sermorelin needs monitoring at all

Sermorelin is a growth-hormone-releasing hormone analog (GHRH 1-29): it prompts your pituitary to release your own growth hormone, which in turn raises insulin-like growth factor 1 (IGF-1), the downstream hormone that carries out most of GH's effects¹. That mechanism is the whole reason monitoring matters. The GH/IGF-1 axis is metabolically active — it influences how your body handles glucose, interacts with thyroid hormone, and (because IGF-1 is a growth signal) is something clinicians watch carefully in anyone with a cancer history. You can't see any of that from how you feel; you see it in labs.

IGF-1: the single most important marker

If a sermorelin program runs only one lab, it should be IGF-1. Because sermorelin acts upstream and your own GH is released in short pulses, a random GH level is nearly useless — but IGF-1 is stable across the day and reflects integrated GH-axis activity, which is why it's the standard marker used to gauge and titrate GH-axis therapy². A baseline IGF-1 tells your clinician whether therapy is even reasonable and gives a number to compare against. Follow-up IGF-1 (typically after several weeks to a couple of months, then periodically) confirms the drug is doing something biochemically and — just as important — that it isn't pushing IGF-1 above the age-appropriate range. Driving IGF-1 too high is not the goal; the aim is restoring a youthful-normal level, not a supraphysiologic one. A provider who never measures IGF-1 has no objective way to dose you or to know whether the therapy is working or overshooting.

Glucose and A1c: the metabolic check

The second core lab is glucose handling — a fasting glucose and usually an HbA1c. Growth-hormone-axis stimulation can affect insulin sensitivity, so glucose is a logical thing to watch. The reassuring news from controlled data on a related GHRH analog (tesamorelin) is that, at therapeutic doses, it did not meaningfully worsen glucose control even in people with type 2 diabetes in a randomized placebo-controlled trial³ — and IGF-1 itself tracks inversely with markers of poor glycemia, so the axis isn't simply “diabetogenic”⁴. But “generally reassuring in trials” is not the same as “no need to check.” A baseline and periodic glucose/A1c catch the individual exception, which is exactly what monitoring is for. We cover the diabetes-medication angle in more depth in sermorelin side effects.

Thyroid: because the GH axis and thyroid talk to each other

A responsible baseline panel usually includes thyroid function (at least TSH, often free T4). The GH and thyroid axes interact — changes in one can unmask or shift the other — so a baseline thyroid picture both screens for an unrelated problem that could explain your symptoms and gives context for interpreting how you respond. We unpack that interaction in sermorelin and thyroid.

PSA and a cancer-history review: the safety screen that isn't optional

This is the lab discussion that separates a careful provider from a careless one. IGF-1 is a growth signal, and higher circulating IGF-1 has been associated with modestly increased risk of certain cancers in large epidemiological analyses — prostate cancer being the best-documented example, where individual-participant meta-analysis links higher IGF-1 to higher risk⁵. That association is about circulating IGF-1 levels in the population, not proof that sermorelin causes cancer — but it's exactly why GH-axis therapies are approached cautiously, and generally avoided, in anyone with active or recent malignancy. Practically, that means a thorough provider takes a cancer history, and for men of the relevant age typically checks a baseline PSA before starting and monitors it. A provider who never asks about cancer history is skipping the most important safety conversation. We go deeper on the cancer question in who should not take sermorelin.

How often, and the honest caveat

A typical cadence is a full baseline panel before starting, a focused recheck (IGF-1, glucose) after roughly 6–12 weeks to confirm response and safe range, and periodic monitoring thereafter. The honest caveat worth stating: this monitoring tells you the drug is biochemically active and staying in a safe range — it does not prove the body-composition or anti-aging benefits sermorelin is marketed for. Sermorelin reliably raises GH and IGF-1 short-term¹, but the broader literature on GH-axis therapy in healthy older adults found small effects offset by a real side-effect burden, and there's no modern outcome trial behind the marketing claims⁶. Labs keep you safe and confirm the mechanism is firing; they don't turn a marker change into a proven outcome. Our pillar evidence guide to sermorelin lays that out in full.

What it means when a provider skips labs

Put plainly: a sermorelin provider who orders no labs at all is a red flag. No baseline IGF-1 means no way to dose or interpret response; no glucose means no metabolic safety check; no cancer-history review and PSA means the most important safety screen is being skipped. No-labs prescribing is one of the markers of a grey-market or corner-cutting operation, which is why lab monitoring is one of the three non-negotiables in our best places to get sermorelin online (2026) guide. Labs cost something (we fold them into the budget in how much does sermorelin cost per month?), but skipping them to save money removes the exact safeguard that makes this medical rather than recreational.

Bottom line

A legitimate sermorelin program checks, at minimum, IGF-1 (the marker that gauges and titrates the therapy), glucose/A1c (the metabolic safety check), thyroid (because the axes interact), and a cancer-history review with PSA in men (the IGF-1-and-cancer safety screen) — at baseline and again on therapy. Those labs are how a provider doses you objectively, keeps IGF-1 in a safe range, and catches problems early. A provider who skips them entirely isn't monitoring the therapy. For who should avoid sermorelin altogether, see who should not take sermorelin; for the full side-effect picture, see sermorelin side effects.